Guelph, ON (November 15, 2016) – Bayer announces the launch of ILeVO™ seed treatment, the first soybean seed treatment registered for Sudden Death Syndrome (SDS) in Canada.
SDS is caused by Fusarium virguliforme. This fungal pathogen overwinters on crop residue and is occurring more frequently in fields across Ontario. Difficult to identify and often misdiagnosed, the disease results in average annual yield loss of about 20 per cent, but can cause losses of up to 60 per cent in a growing season. To date, there have been no seed treatment solutions available for SDS in Canada.
“ILeVO gives growers a way to protect against SDS, a yield robbing pest,” says David Kikkert, crop & campaign marketing manager, soybeans & pulses at Bayer. “As the first seed treatment solution available for SDS in Canada, it’s a revolutionary new way to help protect soybean crops and the growers’ bottom line.”
ILeVO has activity on the Fusarium virguliforme fungus. The effectiveness of the product has been demonstrated through field trials in the US and Canada over the past five years, including third-party trials with OMAFRA and the University of Guelph.
“With the increased cases of SDS in Ontario putting pressure on growers, it’s important to have tools ready to help protect their fields,” said Albert Tenuta, Field Crop Pathologist at OMAFRA. “Growers are continuing to plant in earlier, wetter conditions and reducing the risk of infection at planting will help maximize yields.”
A feature unique to ILeVO which signals a successful application is the “halo effect” which is often visible on the edges of the cotyledons of a treated plant. “ILeVo helps growers protect their soybean fields and helps with the production of higher yielding, healthier soybean plants.” continues Kikkert.
For more information regarding ILeVO, growers are encouraged to talk to their local seed companies and retailers or visit cropscience.bayer.ca/ILeVO .
Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2015, the Group employed around 117,000 people and had sales of EUR 46.3 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.3 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.com.
Note to editors:
Print-quality photos can be downloaded from our website at www.news.bayer.com
TV and multimedia editors can download or order updated film footage about Bayer free of charge at www.tv-footage.bayer.com.
For further information, contact:
This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.